{"database":"biostudies-literature","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":58,"searchCount":0},"additional":{"submitter":["Glinka M"],"funding":["Ministerstvo ??kolstv??, Ml??de??e a T??lov??chovy","Polish programme for PhD students"],"pagination":["2986-2996"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8397404"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(8)"],"pubmed_abstract":["The aim of this study was to fabricate novel microparticles (MPs) for efficient and long-term delivery of amikacin (AMI). The emulsification method proposed for encapsulating AMI employed low-molecular-weight poly(lactic acid) (PLA) and poly(lactic acid-<i>co</i>-polyethylene glycol) (PLA-PEG), both supplemented with poly(vinyl alcohol) (PVA). The diameters of the particles obtained were determined as less than 30 μm. Based on an in-vitro release study, it was proven that the MPs (both PLA/PVA- and PLA-PEG/PVA-based) demonstrated long-term AMI release (2 months), the kinetics of which adhered to the Korsmeyer-Peppas model. The loading efficiencies of AMI in the study were determined at the followings levels: 36.5 ± 1.5 μg/mg for the PLA-based MPs and 106 ± 32 μg/mg for the PLA-PEG-based MPs. These values were relatively high and draw parallels with studies published on the encapsulation of aminoglycosides. The MPs provided antimicrobial action against the <i>Staphylococcus aureus</i>, <i>Escherichia coli</i>, <i>Pseudomonas aeruginosa</i>, and <i>Klebsiella pneumoniae</i> bacterial strains. The materials were also comprehensively characterized by the following methods: differential scanning calorimetry; gel permeation chromatography; scanning electron microscopy; Fourier transform infrared spectroscopy-attenuated total reflectance; energy-dispersive X-ray fluorescence; and Brunauer-Emmett-Teller surface area analysis. The findings of this study contribute toward discerning new means for conducting targeted therapy with polar, broad spectrum antibiotics."],"journal":["Molecular pharmaceutics"],"pubmed_title":["Encapsulation of Amikacin into Microparticles Based on Low-Molecular-Weight Poly(lactic acid) and Poly(lactic acid-<i>co</i>-polyethylene glycol)."],"pmcid":["PMC8397404"],"funding_grant_id":["POWR.03.02.00-00-I002/16","RP/CPS/2020/002"],"pubmed_authors":["Sedlarik V","Wasik A","Glinka M","Bergerova ED","Filatova K","Kucinska-Lipka J"],"view_count":["58"],"additional_accession":[]},"is_claimable":false,"name":"Encapsulation of Amikacin into Microparticles Based on Low-Molecular-Weight Poly(lactic acid) and Poly(lactic acid-<i>co</i>-polyethylene glycol).","description":"The aim of this study was to fabricate novel microparticles (MPs) for efficient and long-term delivery of amikacin (AMI). The emulsification method proposed for encapsulating AMI employed low-molecular-weight poly(lactic acid) (PLA) and poly(lactic acid-<i>co</i>-polyethylene glycol) (PLA-PEG), both supplemented with poly(vinyl alcohol) (PVA). The diameters of the particles obtained were determined as less than 30 μm. Based on an in-vitro release study, it was proven that the MPs (both PLA/PVA- and PLA-PEG/PVA-based) demonstrated long-term AMI release (2 months), the kinetics of which adhered to the Korsmeyer-Peppas model. The loading efficiencies of AMI in the study were determined at the followings levels: 36.5 ± 1.5 μg/mg for the PLA-based MPs and 106 ± 32 μg/mg for the PLA-PEG-based MPs. These values were relatively high and draw parallels with studies published on the encapsulation of aminoglycosides. The MPs provided antimicrobial action against the <i>Staphylococcus aureus</i>, <i>Escherichia coli</i>, <i>Pseudomonas aeruginosa</i>, and <i>Klebsiella pneumoniae</i> bacterial strains. The materials were also comprehensively characterized by the following methods: differential scanning calorimetry; gel permeation chromatography; scanning electron microscopy; Fourier transform infrared spectroscopy-attenuated total reflectance; energy-dispersive X-ray fluorescence; and Brunauer-Emmett-Teller surface area analysis. The findings of this study contribute toward discerning new means for conducting targeted therapy with polar, broad spectrum antibiotics.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2024-02-15T02:59:12.084Z","creation":"2022-02-11T10:02:09.318Z"},"accession":"S-EPMC8397404","cross_references":{"pubmed":["34196555"],"doi":["10.1021/acs.molpharmaceut.1c00193"]}}